Literature DB >> 26460211

Identification of characteristic and prognostic values of chromosome 1p abnormality by multi-gene fluorescence in situ hybridization in multiple myeloma.

F Li1,2, L Hu1, Y Xu1, Z Li1, S Yi1, Z Gu3, C Li1, M Hao1, K Ru1, F Zhan3, A Zetterberg4, W Yuan1, T Cheng1, L Qiu1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26460211     DOI： 10.1038/leu.2015.254

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  [The prognostic impact of 1p21 deletion on newly diagnosed multiple myeloma patients receiving thalidomide-based first-line treatment].

Authors:  Fei Li; Yan Xu; Gang An; Lin-ping Hu; Yan-ru Zhang; Zeng-jun Li; Wei-ping Yuan; Tao Cheng; Lu-gui Qiu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2013-10

2.  A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value.

Authors:  Brian A Walker; Paola E Leone; Laura Chiecchio; Nicholas J Dickens; Matthew W Jenner; Kevin D Boyd; David C Johnson; David Gonzalez; Gian Paolo Dagrada; Rebecca K M Protheroe; Zoe J Konn; David M Stockley; Walter M Gregory; Faith E Davies; Fiona M Ross; Gareth J Morgan
Journal:  Blood       Date:  2010-07-08       Impact factor: 22.113

3.  Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma.

Authors:  W J Chng; M A Gertz; T-H Chung; S Van Wier; J J Keats; A Baker; P L Bergsagel; J Carpten; R Fonseca
Journal:  Leukemia       Date:  2010-03-11       Impact factor: 11.528

4.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

Authors:  John D Shaughnessy; Fenghuang Zhan; Bart E Burington; Yongsheng Huang; Simona Colla; Ichiro Hanamura; James P Stewart; Bob Kordsmeier; Christopher Randolph; David R Williams; Yan Xiao; Hongwei Xu; Joshua Epstein; Elias Anaissie; Somashekar G Krishna; Michele Cottler-Fox; Klaus Hollmig; Abid Mohiuddin; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Jeffrey Sawyer; Yazan Alsayed; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2006-11-14       Impact factor: 22.113

5.  Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients.

Authors:  B Hebraud; X Leleu; V Lauwers-Cances; M Roussel; D Caillot; G Marit; L Karlin; C Hulin; C Gentil; F Guilhot; L Garderet; T Lamy; S Brechignac; B Pegourie; J Jaubert; M Dib; A-M Stoppa; C Sebban; C Fohrer; J Fontan; C Fruchart; M Macro; F Orsini-Piocelle; G Lepeu; C Sohn; J Corre; T Facon; P Moreau; M Attal; H Avet-Loiseau
Journal:  Leukemia       Date:  2013-07-29       Impact factor: 11.528

6.  Prognostic significance of copy-number alterations in multiple myeloma.

Authors:  Hervé Avet-Loiseau; Cheng Li; Florence Magrangeas; Wilfried Gouraud; Catherine Charbonnel; Jean-Luc Harousseau; Michel Attal; Gerald Marit; Claire Mathiot; Thierry Facon; Philippe Moreau; Kenneth C Anderson; Loïc Campion; Nikhil C Munshi; Stéphane Minvielle
Journal:  J Clin Oncol       Date:  2009-08-17       Impact factor: 44.544

7.  Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant.

Authors:  Muzaffar H Qazilbash; Rima M Saliba; Bilal Ahmed; Gaurav Parikh; Floralyn Mendoza; Noman Ashraf; Chitra Hosing; Thuy Flosser; Donna M Weber; Michael Wang; Daniel R Couriel; Uday Popat; Partow Kebriaei; Amin M Alousi; Paolo Anderlini; Rizwan C Naeem; Richard E Champlin; Sergio A Giralt
Journal:  Biol Blood Marrow Transplant       Date:  2007-07-16       Impact factor: 5.742

Review 8.  IMWG consensus on risk stratification in multiple myeloma.

Authors:  W J Chng; A Dispenzieri; C-S Chim; R Fonseca; H Goldschmidt; S Lentzsch; N Munshi; A Palumbo; J S Miguel; P Sonneveld; M Cavo; S Usmani; B G M Durie; H Avet-Loiseau
Journal:  Leukemia       Date:  2013-08-26       Impact factor: 11.528

9.  Initial genome sequencing and analysis of multiple myeloma.

Authors:  Michael A Chapman; Michael S Lawrence; Jonathan J Keats; Kristian Cibulskis; Carrie Sougnez; Anna C Schinzel; Christina L Harview; Jean-Philippe Brunet; Gregory J Ahmann; Mazhar Adli; Kenneth C Anderson; Kristin G Ardlie; Daniel Auclair; Angela Baker; P Leif Bergsagel; Bradley E Bernstein; Yotam Drier; Rafael Fonseca; Stacey B Gabriel; Craig C Hofmeister; Sundar Jagannath; Andrzej J Jakubowiak; Amrita Krishnan; Joan Levy; Ted Liefeld; Sagar Lonial; Scott Mahan; Bunmi Mfuko; Stefano Monti; Louise M Perkins; Robb Onofrio; Trevor J Pugh; S Vincent Rajkumar; Alex H Ramos; David S Siegel; Andrey Sivachenko; A Keith Stewart; Suzanne Trudel; Ravi Vij; Douglas Voet; Wendy Winckler; Todd Zimmerman; John Carpten; Jeff Trent; William C Hahn; Levi A Garraway; Matthew Meyerson; Eric S Lander; Gad Getz; Todd R Golub
Journal:  Nature       Date:  2011-03-24       Impact factor: 49.962

10.  Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.

Authors:  Fei Li; Yan Xu; Ping Deng; Ye Yang; Weiwei Sui; Fengyan Jin; Mu Hao; Zengjun Li; Meirong Zang; Dehui Zhou; Zhimin Gu; Kun Ru; Jianxiang Wang; Tao Cheng; Lugui Qiu
Journal:  Oncotarget       Date:  2015-04-20
View more
  5 in total

Review 1.  The TRIM proteins in cancer: from expression to emerging regulatory mechanisms.

Authors:  A Mohammadi; M S Pour Abbasi; S Khorrami; S Khodamoradi; Z Mohammadi Goldar; F Ebrahimzadeh
Journal:  Clin Transl Oncol       Date:  2021-10-13       Impact factor: 3.405

2.  A proof-of-concept study for the pathogenetic role of enhancer hypomethylation of MYBPHL in multiple myeloma.

Authors:  Kwan Yeung Wong; Gareth J Morgan; Eileen M Boyle; Alfred Sze Lok Cheng; Kevin Yuk-Lap Yip; Chor Sang Chim
Journal:  Sci Rep       Date:  2021-03-26       Impact factor: 4.379

Review 3.  Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications.

Authors:  Ignacio J Cardona-Benavides; Cristina de Ramón; Norma C Gutiérrez
Journal:  Cells       Date:  2021-02-05       Impact factor: 6.600

Review 4.  TRIM proteins in blood cancers.

Authors:  Lisa J Crawford; Cliona K Johnston; Alexandra E Irvine
Journal:  J Cell Commun Signal       Date:  2017-11-06       Impact factor: 5.782

5.  [Effect of 1q21 amplification on bortezomib therapeutic response and prognosis of newly diagnosed multiple myeloma patients].

Authors:  X L Liu; P Y Yang; X Y Yu; J C Chen; X L Liu; J Bai; Y M Liu; H He; J N Sun; H Q Fan; C Zhang; Y Zhang; K J Su; C S Liu; Y H Tan; S J Gao; W Li; F Y Jin
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-05-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.